Cellular delivery in vivo of siRNA-based therapeutics

A Aigner - Current pharmaceutical design, 2008 - ingentaconnect.com
RNAi interference (RNAi) is an almost standard method for the knockdown of any target
gene of interest in vitro, exploring a naturally occurring catalytic mechanism. Beyond …

Tumor-targeted delivery of siRNA by self-assembled nanoparticles

SD Li, YC Chen, MJ Hackett, L Huang - Molecular Therapy, 2008 - cell.com
We have developed a self-assembled nanoparticle (NP) that efficiently delivers small
interfering RNA (siRNA) to the tumor by intravenous (IV) administration. The NP was …

Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice

N Murata, Y Takashima, K Toyoshima… - Journal of Controlled …, 2008 - Elsevier
The suppression of gene expression of vascular endothelial growth factor (VEGF) which
regulates tumor angiogenesis in vivo and is an important factor in tumor growth represents a …

[引用][C] RNAi 及其在肿瘤基因治疗中的应用研究进展

邹小龙, 乔海泉 - 临床误诊误治, 2008

[引用][C] siRNA 非病毒载体的研究进展

王曦培, 于凤波, 李宇婷, 姜同英, 王思玲 - 世界临床药物, 2008

[引用][C] ЭФФЕКТИВНОСТЬ ПРЕПАРАТА ТЕРАФЛЕКС-АДВАНС В ЛЕЧЕНИИ БОЛЕВОГО СИНДРОМА ПРИ ОСТЕОАРТРОЗЕ КОЛЕННЫХ СУСТАВОВ

ВВ Повороонюк, НИ Дзерович - Научно-практическая ревматология, 2008 - elibrary.ru